Efficacy of direct-acting antiviral agents combined regimens for hepatitis C virus with different genotypes in Dehong Prefecture， Yunnan Province from 2022 to 2024
10.19428/j.cnki.sjpm.2025.24877
- VernacularTitle:2022—2024年云南省德宏州应用直接抗病毒药物联合方案治疗不同基因型丙型肝炎的疗效
- Author:
Renhai TANG
1
;
Yidan ZHAO
2
;
Yuecheng YANG
1
;
Runhua YE
1
;
Lifen XIANG
1
;
Xingmei FENG
1
;
Qunbo ZHOU
1
;
Yanfen CAO
1
;
Na HE
2
;
Yingying DING
2
;
Song DUAN
1
Author Information
1. Dehong Prefecture Center for Disease Control and Prevention, Mangshi, Yunnan 678400, China
2. Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
- Publication Type:Journal Article
- Keywords:
hepatitis C virus;
genotype;
medication regimen;
direct-acting antiviral agent;
efficacy
- From:
Shanghai Journal of Preventive Medicine
2025;37(8):676-681
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the therapeutic effects of direct-acting antiviral agents (DAAs) combined regimens for hepatitis C virus (HCV) patients in Dehong Prefecture, Yunnan Province from 2022 to 2024, to analyze the characteristics of treatment failure patients, so as to provide a basis for discovering more effective treatment regimens in the future. MethodsData on HCV prevention and treatment in Dehong Prefecture was extracted from the China Disease Control and Prevention Information System. A total of 617 patients with HCV antiviral therapy were included, and the differences in variable characteristics among patients with different genotypes were analyzed using comparative statistical tests, including basic socio-demographic characteristics, biochemical testing indicators, and information on previous treatment and current treatment. In addition, the cure rate of HCV patients with diverse characteristics was compared, and the potential causes of treatment failure were explored simultaneously. ResultsThe cure rate of HCV was 96.8%, and statistically significant differences were observed in aspartate transaminase (AST) and alanine transaminase (ALT) levels, previous antiviral therapy history and initial treatment regimens among patients with different HCV genotypes (all P<0.05). Among the multi-type combination regimens, the cure rate of sofosbuvir (SOF)-containing regimens was 97.00%, that of velpatasvir (VEL)-containing regimens was 95.45%, and the cure rate of other treatment regimens, including the regimens with ribavirin (RIB) intervention, was 93.10%. Among the patients with treatment failure, 45.00% had genotype 3, 40.00% had abnormal abdominal ultrasound results, and all presented with elevated baseline AST test levels. ConclusionThe clinical treatment of HCV patients should consider the differences in genotype and biochemical test results. DAAs combined regimens for HCV have achieved a high cure rate in Dehong Prefecture and are applicable to HCV patients with diverse clinical characteristics, providing research evidence for wider application.
